AI Article Synopsis
Article Abstract
Objective: This study aimed to investigate spousal information concealment in patients with cancer and analyse its influencing factors.
Methods: Between April and July 2024, 371 spouses of patients with cancer were surveyed using the Demographic and Clinical Characteristics Questionnaire, the Information Concealment Scale for Caregivers, Fear of Progression Questionnaires for Partners, and the Medical Coping Modes Questionnaire. Influencing factors were analysed using latent profile analysis.
Results: Based on the degree of information concealment, spouses of patients with cancer were categorised into three subgroups: the low concealment - low control (19.14%), medium concealment (50.40%), and high concealment - high dissimulation group (30.46%). Multivariate logistic regression analysis revealed that sex, age, educational level, disease stage, fear of disease progression, and medical coping modes were the influencing factors of the information concealment subgroups (＜0.05).
Conclusions: Information concealment among spouses of patients with cancer has individualized characteristics. Analysing the demographics, disease features, and psychological conditions of spouses in different information concealment subgroups can help medical staff formulate more targeted and personalized interventions and reduce the degree of information concealment among patients' spouses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667617 | PMC |
| http://dx.doi.org/10.1016/j.apjon.2024.100626 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safe Laparoscopic Treatment of a Giant Hepatic Cyst That Compressed the Inferior Vena Cava With Severe Kyphosis.
Asian J Endosc Surg
December 2024
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
We report a case in which a giant hepatic cyst located at the hepatic hilum and compressing the inferior vena cava was safely treated laparoscopically with careful attention to hemodynamics in a difficult fenestrated resection in a patient with severe kyphosis. The anatomic location of the cyst was evaluated preoperatively via 3D reconstruction of computed tomography images to identify a site where safe fenestrated resection could be performed. This was challenging because the surgical field was narrow due to the presence of severe kyphosis, and there was a risk of damage to surrounding organs during fenestrated resection.
View Article and Find Full Text PDFOutcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience.
Oncologist
December 2024
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, United States.
Background: Sarcomatoid carcinomas (SC) are rare tumors with both epithelial and mesenchymal characteristics, linked to aggressive behavior and poor prognosis. Sarcomatoid carcinoma of unknown primary (SCUP) is an exceedingly rare subset with limited literature and no standardized management guidelines. This study aims to characterize the clinical presentations, treatment patterns, and genomic landscape of SCUP.
View Article and Find Full Text PDFCell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses.
Cell Rep
December 2024
Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada; Toronto General Hospital Research Institute, Ajmera Transplant Centre, University Health Network, Toronto, ON M5G 1L7, Canada. Electronic address:
Interleukin-10 (IL-10)-producing group 2 innate lymphoid cells (ILC2) regulate inflammatory immune responses, yet their therapeutic potential remains largely unexplored. Here, we demonstrate that cell therapy with human ILC2 inhibits pathogenic T cell responses in humanized mouse models of graft-versus-host disease (GVHD), resulting in reduced GVHD severity and improved overall survival without limiting the graft-versus-leukemia effect. ILC2 conferred superior protection from GVHD than IL-10 ILC2s, and blocking IL-10 and IL-4 abrogated ILC2 protective effects, indicating that these cytokines are important for the protective effects of ILC2.
View Article and Find Full Text PDFA phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling.
Oncologist
December 2024
The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW 2010, Australia.
Background: TRK-inhibitors have demonstrated efficacy across several cancers with NTRK fusions. Their activity in cancers with NTRK overexpression remains unclear.
Methods: This trial enrolled patients with advanced cancers harboring NTRK fusions or extreme mRNA overexpression, defined as NTRK1/2/3 expression by RNA profiling >5 SDs for a given cancer type.
Efficacy and mechanisms of curcumin in the treatment of osteoarthritis: A scoping review.
Biomol Biomed
December 2024
Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Malaysia.
Osteoarthritis (OA) is a degenerative joint disease that primarily affects the elderly worldwide. It is characterized by local inflammation, which can be targeted therapeutically using natural anti-inflammatory compounds such as curcumin. This scoping review explores the therapeutic effects and mechanisms of curcumin in OA management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!